Effect of GSK2586881 on plasma cytokines
| Controls | Time after drug administration | |||||
| 0 h | 2 h | 4 h | 24 h | 2 weeks | ||
| IFN-γ pg·mL−1 | 8.4±5.1 | 17.1±10.9 | 14.9±12.9 | 15.4±9.8¶ | 20.5±17.8 | 15.7±11.2 |
| IL-10 pg·mL−1 | 6.6±5.5 | 15.9±5.3# | 12.0±3.8¶ | 13.8±6.6 | 19.1±10.4 | 13.6±9.1 |
| IL-13 pg·mL−1 | 11.6±9.5 | 39.1±15.0# | 30.3±14.3 | 32.9±14.2¶ | 41.0±22.2 | 34.9±18.6 |
| IL-1β pg·mL−1 | 1.3±0.5 | 3.8±2.0# | 2.6±1.8¶ | 3.0±1.7+ | 4.3±3.2 | 3.0±1.8¶ |
| IL-2 pg·mL−1 | 3.1±1.4 | 6.3±3.0 | 4.8±3.0 | 5.6±2.8¶ | 7.1±5.2 | 5.6±2.6 |
| IL-4 pg·mL−1 | 14.0±11.4 | 42.8±26.5# | 34.5±23.3 | 35.7±19.7 | 50.0±35.7 | 36.9±27.3 |
| IL-6 pg·mL−1 | 2.5±1.8 | 4.6±1.8 | 4.0±1.9 | 9.2±6.7 | 6.4±6.4 | 3.3±1.5+ |
| IL-8 pg·mL−1 | 5.0±1.6 | 8.6±1.5# | 7.5±2.5 | 8.5±1.6 | 9.2±2.9 | 6.9±1.4¶ |
| TNF-α pg·mL−1 | 4.8±3.2 | 9.1±1.8# | 5.6±3.0¶ | 6.8+±1.9 | 9.6±5.3 | 5.2±1.5¶ |
Data are presented as mean±sd for five healthy controls and five pulmonary arterial hypertension patients treated with angiotensin-converting enzyme 2. IFN: interferon; IL: interleukin; TNF: tumour necrosis factor. #: p<0.05 versus controls by paired t-test with normalised data; ¶: p<0.05 versus pre-treatment (time-point 0 h) by paired t-test with normalised data; +: p<0.01 versus pre-treatment (time-point 0 h) by paired t-test with normalised data.